文献速递浆细胞疾病淋巴瘤

PIM2激酶在浆母细胞生成和浆细胞存活中起关键作用,为骨髓瘤开辟新的治疗选择

PIM2 kinase has a pivotal role in plasmablast generation and plasma cell survival, opening up novel treatment options in myeloma.
PubMed 文献 · Blood · 2022-01-01

该研究采用特异性抑制策略(包括新型吗啉代RNA反义方法),发现Moloney病毒整合位点2(PIM2)激酶在体外人类B细胞分化过程中早期持续上调,并在骨髓成熟正常和恶性浆细胞中持续表达。PIM2通过作用于CDC25A和p27Kip1维持G1/S转换,并通过BAD磷酸化和p21Cip1胞质稳定阻碍caspase 3驱动的凋亡。在多发性骨髓瘤中,pan-PIM和MCL1抑制剂显示出协同活性,作者认为这些发现应促使重新考虑PIM2作为多发性骨髓瘤的治疗靶点。

要点

  • PIM2激酶在人类B细胞体外分化中早期持续上调,并在骨髓成熟正常和恶性浆细胞中持续表达。
  • PIM2通过CDC25A和p27Kip1维持G1/S转换,并通过BAD磷酸化和p21Cip1胞质稳定阻碍caspase 3驱动的凋亡。
  • 在多发性骨髓瘤中,pan-PIM和MCL1抑制剂显示出协同活性,作者认为这些发现应促使重新考虑PIM2作为治疗靶点。

核心结论

  • PIM2激酶在人类B细胞体外分化为浆母细胞和浆细胞过程中起关键作用,并在骨髓成熟正常和恶性浆细胞中持续表达。
  • 在浆细胞中,白细胞介素-6触发PIM2表达,产生抗凋亡效应,恶性浆细胞尤其依赖该效应。
  • 作者认为这些发现应促使重新考虑PIM2作为多发性骨髓瘤的治疗靶点。

研究设计与样本

  • 研究采用特异性抑制策略,包括一种新型吗啉代RNA反义方法,在人类B细胞体外分化体系及骨髓正常和恶性浆细胞中进行。

主要发现

  • PIM2通过作用于CDC25A和p27Kip1维持G1/S转换,并通过BAD磷酸化和p21Cip1胞质稳定阻碍caspase 3驱动的凋亡。
  • 在浆细胞中,白细胞介素-6触发PIM2表达,产生抗凋亡效应,恶性浆细胞尤其依赖该效应。
  • 在多发性骨髓瘤中,pan-PIM和MCL1抑制剂显示出协同活性。

临床怎么用

  • 作者认为这些发现应促使重新考虑PIM2作为多发性骨髓瘤的治疗靶点。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The differentiation of B cells into plasmablasts (PBs) and then plasma cells (PCs) is associated with extensive cell reprogramming and new cell functions. By using specific inhibition strategies (including a novel morpholino RNA antisense approach), we found that early, sustained upregulation of the proviral integrations of Moloney virus 2 (PIM2) kinase is a pivotal event during human B-cell in vitro differentiation and then continues in mature normal and malignant PCs in the bone marrow. In particular, PIM2 sustained the G1/S transition by acting on CDC25A and p27Kip1 and hindering caspase 3-driven apoptosis through BAD phosphorylation and cytoplasmic stabilization of p21Cip1. In PCs, interleukin-6 triggered PIM2 expression, resulting in antiapoptotic effects on which malignant PCs were particularly dependent. In multiple myeloma, pan-PIM and myeloid cell leukemia-1 (MCL1) inhibitors displayed synergistic activity. Our results highlight a cell-autonomous function that links kinase activity to the newly acquired secretion ability of the PBs and the adaptability observed in both normal and malignant PCs. These findings should finally prompt the reconsideration of PIM2 as a therapeutic target in multiple myeloma.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Haas M, Caron G, Chatonnet F, et al. PIM2 kinase has a pivotal role in plasmablast generation and plasma cell survival, opening up novel treatment options in myeloma. Blood. 2022. PMID: 35108359. doi:10.1182/blood.2021014011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。